See more : ANSYS, Inc. (ANSS) Income Statement Analysis – Financial Results
Complete financial analysis of Allena Pharmaceuticals, Inc. (ALNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allena Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Amulaire Thermal Technology, Inc. (2241.TW) Income Statement Analysis – Financial Results
- O2 Czech Republic a.s. (TFAOF) Income Statement Analysis – Financial Results
- Spartan Acquisition Corp. III (SPAQ-UN) Income Statement Analysis – Financial Results
- Summit Healthcare Acquisition Corp. (SMIH) Income Statement Analysis – Financial Results
- Atari SA (PONGF) Income Statement Analysis – Financial Results
Allena Pharmaceuticals, Inc. (ALNA)
About Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.38M | 20.38M | 37.24M | 26.38M | 15.52M | 20.10M | 11.54M |
| General & Administrative | 11.60M | 11.60M | 9.68M | 8.64M | 5.43M | 4.08M | 2.37M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 576.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 11.60M | 11.60M | 9.68M | 9.22M | 5.43M | 4.08M | 2.37M |
| Other Expenses | 0.00 | 0.00 | 605.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 31.99M | 31.99M | 46.92M | 35.59M | 20.95M | 24.19M | 13.91M |
| Cost & Expenses | 31.99M | 31.99M | 46.92M | 35.59M | 20.95M | 24.19M | 13.91M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 510.00K | -510.00K | 270.00K | 575.00K | -443.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 363.00K | 166.00K | 163.00K | 78.00K | 73.00K | 46.00K | 98.00K |
| EBITDA | -31.97M | -32.68M | -47.18M | -35.57M | -21.58M | -24.46M | -14.15M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.34M | -31.99M | -46.92M | -35.59M | -20.95M | -24.19M | -13.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -510.00K | -859.00K | 0.00 | -55.00K | -700.00K | -321.00K | -342.00K |
| Income Before Tax | -32.85M | -32.85M | -47.34M | -35.65M | -21.65M | -24.51M | -14.25M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 510.00K | -859.00K | -419.00K | -55.00K | -700.00K | -321.00K | -342.00K |
| Net Income | -33.36M | -32.85M | -47.34M | -35.65M | -21.65M | -24.51M | -14.25M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.03 | -1.01 | -2.13 | -1.72 | -4.79 | -1.60 | -0.93 |
| EPS Diluted | -1.03 | -1.01 | -2.13 | -1.72 | -4.79 | -1.60 | -0.93 |
| Weighted Avg Shares Out | 32.51M | 32.51M | 22.18M | 20.74M | 4.52M | 15.28M | 15.29M |
| Weighted Avg Shares Out (Dil) | 32.51M | 32.51M | 22.18M | 20.74M | 4.52M | 15.28M | 15.29M |
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
Contrasting Allena Pharmaceuticals (NASDAQ:ALNA) & Audentes Therapeutics (NASDAQ:BOLD)
ALLN Walking Into Life for Bringing Various Applications - Coin News Asia
Allena Pharmaceuticals Completes $53M Series C Financing |FinSMEs
Source: https://incomestatements.info
Category: Stock Reports